Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma
Table 1
Baseline demographics and clinical characteristics.
TLV ()
ETV ()
value
Age, years
56.1 ± 9.5
60.5 ± 8.3
0.024
Male
31/8 (79%)
39/8 (76%)
0.683
CP class (A/B/C)
23/10/6
31/15/1
0.148
ALT, IU/L
89.6 ± 92.8
66.5 ± 134.3
0.365
Prothrombin time, INR
1.25 ± 0.22
1.22 ± 0.12
0.402
Albumin, g/dL
3.19 ± 0.61
3.41 ± 0.57
0.098
Total bilirubin, mg/dL
2.14 ± 1.93
1.36 ± 0.70
0.012
Platelet count, 103/mL
175.5 ± 80.2
120.7 ± 64.4
0.001
Median alpha-fetoprotein (range), ng/mL
3859.5 (985558.3)
69.43 (33776.3)
0.003
HBV DNA, IU/mL
5.91 ± 0.96
5.92 ± 1.33
0.968
HBeAg positivity
21 (53.8%)
25 (53.1%)
0.952
Tumor stage, TNM stages I/II/III/IVa/IVb
0/3/7/15/14
8/15/9/8/7
0.000
Death
27/39 (69.2%)
16/47 (34%)
0.001
Treatment modality
RFA
0
2 (5.1%)
Hepatectomy
2 (4.2%)
12 (30.7%)
TACE
32 (82%)
33 (70.2%)
Sorafenib
2 (4.2%)
0
RT
0
0
Conservative care
3 (6.3%)
0
Variables are expressed as means ± standard deviation (SD), medians (ranges), or (%). TLV, telbivudine; ETV, entecavir; CP, Child-Pugh; ALT, alanine transaminase; INR, international normalized ratio; HBeAg, hepatitis B e antigen; TNM, tumor-node-metastasis; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; and RT, radiation therapy.
